Search

Your search keyword '"AKALIN, H."' showing total 323 results
Start Over Author "AKALIN, H."
323 results on '"AKALIN, H."'

2. The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma

Author

Yildiz OG, Aslan D, Akalin H, Erdem Y, Canoz O, Aytekin A, Ozoner S, and Dundar M

Subjects
glioblastoma (gb), o6-methyl guanine methyl transferase (mgmt) methylation, radiotherapy (rt), Genetics, QH426-470
Abstract

This retrospective study examined the prognostic significance and treatment effect of promoter methylation of O6- methyl guanine methyl transferase (MGMT) and meth-ylation of CpG 1, CpG2, CpG3 and CpG4 in glioblastoma (GB) patients received postoperative radiotherapy (PORT), with or without adjuvant temozolomide (TMZ). One hundred patients with GB who received PORT with concomitant TMZ plus adjuvant TMZ or PORT alone, were included. The MGMT promoter methylation of CpG1, CpG2, CpG3 and CpG4 islands were examined. Overall, MGMT-methylation emerged as a significant prognostic factor for better overall survival (OS) and progression-free survival (PFS) [odds ratio (OR): 0.609, 95% confidence interval (95% CI): 0.395-0.939, p = 0.02; OR: 0.662,95% CI: 0.430-1019, p = 0.5, respectively]. The methylation of each CpG1, CpG2, CpG3 and CpG4 islands was found to have no significant effects on OS and the methylation of each CpGl, CpG2 and CpG4 islands had no significant effect on PFS (p

Published
2020
Full Text
View/download PDF

8. A novel β-lactam-aminoglycoside combination in veterinary medicine: The couse of ceftiofur and gentamicin to combat resistant Escherichia coli

Author

CENGIZ, M., SAHINTURK, P., HEPBOSTANCI, G., AKALIN, H., and SONAL, S.

Subjects
antimicrobial combination, resistant Escherichia coli, Ceftiofur, gentamicin
Abstract

ΔΕΝ ΔΙΑΤΙΘΕΤΑΙ ΠΕΡΙΛΗΨΗ, The focus of this study was to evaluate the efficacy of ceftiofur+gentamicin combination to increase the success of antimicrobial inhibition against resistant Escherichia coli (E.coli) strains isolated from animals. Interaction between drugs was determined using checkerboard method and the fractional inhibitory concentration index was interpreted as synergism, antagonism and indifference. The combination was defined as bactericidal or bacteriostatic based on the minimum bactericidal test results. Mutant prevention concentration test was used to evaluate the resistance tendency suppression potential of the combination. The synergistic effect was detected for all E. coli strains by the checkerboard method; even the strains that were resistant to the individual compounds in the combination. Based on the results of minimum bactericidal concentration test, the combination exhibited bactericidal effect against all E. coli strains. In addition, the individual mutant prevention concentrations of ceftiofur and gentamicin decreased up to 125-fold by using the combination for the inhibition of resistant E. coli strains. The results indicated that killing potential of co-use of the compounds is much stronger than their individual use. The combination achieved to decrease the mutant prevention concentrations and this can reduce the risk of emergence of single mutations during treatment done with suggested doses.

Published
2020

9. A Novel Beta-Lactam-Aminoglycoside Combination In Veterinary Medicine: The Couse Of Ceftiofur And Gentamicin To Combat Resistant Escherichia Coli

Author

Cengiz, M., Sahinturk, P., Hepbostanci, G., Akalin, H., and Sonal, S.

Abstract

The focus of this study was to evaluate the efficacy of ceftiofur+gentamicin combination to increase the success of antimicrobial inhibition against resistant Escherichia coli (E.coli) strains isolated from animals. Interaction between drugs was determined using checkerboard method and the fractional inhibitory concentration index was interpreted as synergism, antagonism and indifference. The combination was defined as bactericidal or bacteriostatic based on the minimum bactericidal test results. Mutant prevention concentration test was used to evaluate the resistance tendency suppression potential of the combination. The synergistic effect was detected for all E. coli strains by the checkerboard method; even the strains that were resistant to the individual compounds in the combination. Based on the results of minimum bactericidal concentration test, the combination exhibited bactericidal effect against all E. coli strains. In addition, the individual mutant prevention concentrations of ceftiofur and gentamicin decreased up to 125-fold by using the combination for the inhibition of resistant E. coli strains. The results indicated that killing potential of co-use of the compounds is much stronger than their individual use. The combination achieved to decrease the mutant prevention concentrations and this can reduce the risk of emergence of single mutations during treatment done with suggested doses.

Published
2020

12. HIV cascade of care in Turkey: data from the HIV-TR cohort

Author

Gokengin, D., Cimen, C., Cagatay, A., Gencer, S., Akalin, H., Ceran, N., Korten, V., Ondokuz Mayıs Üniversitesi, and Ege Üniversitesi

Abstract

Gokengin, Ayse/0000-0003-0704-2302, WOS: 000494690300226, [No abstract available]

Published
2019

26. Efficiency evaluation for wind turbines using stochastic frontier analysis [Stokastik sinir analizi kullanarak rözgâr törbinleri için etkinlik degerlendirmesi]

Author

Akalin H., Seçkiner S.U., Eroglu Y., and İskenderun Teknik Üniversitesi

Subjects
Stochastic frontier analysis, Performance evaluation, Wind turbine
Abstract

In this paper, Stochastic Frontier Analysis (SFA) technique is contributed to measure the productive efficiency of a working wind farm. In the current literature SFA, which is one of the commonly used efficiency analysis tool in many different areas, has not been studied previously to measure wind turbine efficiencies. Stochastic nature is the key advantage of SFA, whereby frontier deviations include both external effects that are not within the company's control and technical inefficiency. The proposed approach was used to calculate efficiency of each wind turbines to compare each other and to determine whole wind farm efficiency according to four different cases. These cases were introduced to determine the effects of different input parameters on the efficiency levels. Thereby, the other crucial interest of this study is to answer which factors are effective to measure the efficiency of a wind turbine by implementing four different input oriented cases. Also, these four cases studied under three different time periods; monthly averaged data, twelve monthly averaged data, and twenty four monthly data. Results showed that different input groups gave different efficiency results. Whether the efficiency loses originated from statistical noise or technical inefficiency could be concluded by the advantage of SFA.

Published
2017

27. The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma.

Author

Yildiz, OG, Aslan, D, Akalin, H, Erdem, Y, Canoz, O, Aytekin, A, Ozoner, S, and Dundar, M

Subjects
METHYLATION, TREATMENT effectiveness, PROGRESSION-free survival, ODDS ratio, BIOMARKERS
Abstract

This retrospective study examined the prognostic significance and treatment effect of promoter methylation of O6- methyl guanine methyl transferase (MGMT) and meth-ylation of CpG 1, CpG2, CpG3 and CpG4 in glioblastoma (GB) patients received postoperative radiotherapy (PORT), with or without adjuvant temozolomide (TMZ). One hundred patients with GB who received PORT with concomitant TMZ plus adjuvant TMZ or PORT alone, were included. The MGMT promoter methylation of CpG1, CpG2, CpG3 and CpG4 islands were examined. Overall, MGMT-methylation emerged as a significant prognostic factor for better overall survival (OS) and progression-free survival (PFS) [odds ratio (OR): 0.609, 95% confidence interval (95% CI): 0.395-0.939, p = 0.02; OR: 0.662,95% CI: 0.430-1019, p = 0.5, respectively]. The methylation of each CpG1, CpG2, CpG3 and CpG4 islands was found to have no significant effects on OS and the methylation of each CpGl, CpG2 and CpG4 islands had no significant effect on PFS (p <0.05 for all). On the other hand, the methylation of CpG3 had a positive prognostic effect on PFS (OR: 2.1, 95% CI: 0.99-4.67, p = 0.04). In the group that only received radiotherapy (RT), CpG1 and CpC3 methylations were found to have a positive prognostic significance in terms of PFS (OR: 266, 95% CI: 1.05-6.75, p -0.03 for CpG1; OR: 2.4, 95% CI: 1.01-5.92, p = 0.04 for CpG3). The MGMT promoter methylation represents an important biomarker for predicting response to therapy. Individual islands, particularly CpG3, deserves further investigation as a prognostic marker. Further studies need to be done with larger sample sizes to clarify the results. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

30. Antiretroviral-Naive Patients in Turkey

Author

Sayan, M, Sargin, F, Inan, D, Sevgi, DY, Celikbas, AK, Yasar, K, Kaptan, F, Kutlu, S, Fisgin, NT, Inci, A, Ceran, N, Karaoglan, I, Cagatay, A, Celen, MK, Koruk, ST, Ceylan, B, Yildirmak, T, Akalin, H, Korten, V, and Willke, A

Abstract

HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts.

Published
2016

31. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in

Author

Sayan, M, Gunduz, A, Ersoz, G, Inan, A, Deveci, A, Ozgur, G, Sargin, F, Karagoz, G, Inci, A, Inan, D, Ulcay, A, Karaoglan, I, Kaya, S, Kutlu, SS, Suer, K, Cagatay, A, and Akalin, H

Subjects
virus diseases, Dolutegravir, Drug Resistance, Dna Sequencing, Hiv-1 Integrase, Integrase Inhibitors, Raltegravir, Elvitegravir
Abstract

Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients. Methods: This study was conducted in Turkey, between April 2013 and April 2015 using 169 HIV-1-infected patients (78 ARV naive patients and 91 ARV-experienced patients). Laboratory and clinical characteristics of ARV naive and ARV-experienced patients were as follows: gender (M/F): 71/7 and 80/11, median age: 38 and 38.4; median CD4+ T-cell: 236 and 216 cells/mm3, median HIV-1 RNA: 4.95+ E5 and 1.08E+ 6 copies/ml. Population-based seqeunces of the reverse transcriptase, protease, and integrase domains of the HIV-1 pol gene were used to detect HIV-1 drug resistance mutations. Result: INSTI resistance mutations were not found in recently diagnosed HIV-1-infected patients. However, ARV-experienced patients had major resistance mutations associated with raltegravir and elvitegravir; the following results were generated: F121Y, Y143R, Q148R and E157Q (6/91 - 6.6%). Conclusions: The prevalence of INSTI resistant mutations in ART-experienced patients suggested that resistance testing must be incorporated as an integral part of HIV management with INSTI therapies.

Published
2016

40. A multicenter point-prevalence study: antimicrobial prescription frequencies in hospitalized patients in turkey

Author

Usluer G., Ozgunes I., Leblebicioglu H., Akalin H., Ayaz C., Caylan R., Yamazhan T., and OMÜ

Subjects
Microbiology (medical), medicine.medical_specialty, Cost, Appropriate antimicrobial use, lcsh:QR1-502, Prevalence, Drug resistance, lcsh:Microbiology, Drug Costs, lcsh:Infectious and parasitic diseases, Anti-Infective Agents, Internal medicine, Intensive care, cost, medicine, Humans, lcsh:RC109-216, Prospective Studies, Antibiotic prophylaxis, Elective surgery, Medical prescription, Intensive care medicine, appropriate antimicrobial use, business.industry, Research, lcsh:RM1-950, General Medicine, Antibiotic Prophylaxis, Antimicrobial, medicine.disease, antimicrobial use, Drug Utilization, Hospitalization, Antimicrobial use, lcsh:Therapeutics. Pharmacology, Infectious Diseases, Drug Therapy, Combination, business, Febrile neutropenia
Abstract

Background Accurate information about prescribing patterns in hospitals is valuable in improving the quality of antimicrobial prescriptions. Methods Data on the use of antimicrobial agents in eighteen tertiary care hospitals were collected on March 20th 2002. Results One or more antimicrobials were ordered in 2900 (30.6 %)of 9471 hospitalized patients. The reasons of hospitalization of the patients receiving antimicrobials were medical treatment (42.5 %), elective surgery (39.6 %), treatment of infectious disease (17.1 %) and emergent surgical procedures (10.4 %). The highest consumption frequencies were found in surgical (81.6 %) and medical (55.2 %) intensive care units. The 48.8 % of antimicrobials were given for treatment and 44.2 % for prophylactic use. The most common reasons for treatment were found as lower respiratory tract, urinary tract, surgical wound infections and febrile neutropenia. Antimicrobials were ordered empirically in 78.4 % of patients. The proven infection ratio was found as 30.7 %. The 56.4 % and 13.4 % of orders were evaluated as clinically and microbiologically appropriate respectively. Conclusion These results suggest that antimicrobial prescription and empirical treatment ratios were high and inappropriate at inpatient groups.

Published
2005
Full Text
View/download PDF

44. TRANSPLANTATION BASIC SCIENCE, ALLOGENIC AND XENOGENIC TOLERANCE

Author

Berthelot, L., primary, Robert, T., additional, Tabary, T., additional, Vuiblet, V., additional, Drame, M., additional, Toupance, O., additional, Rieu, P., additional, Monteiro, R. C., additional, Toure, F., additional, Ferrario, S., additional, Cantaluppi, V., additional, De Lena, M., additional, Dellepiane, S., additional, Beltramo, S., additional, Rossetti, M., additional, Manzione, A. M., additional, Messina, M., additional, Gai, M., additional, Dolla, C., additional, Biancone, L., additional, Camussi, G., additional, Pontrelli, P., additional, Oranger, A. R., additional, Accetturo, M., additional, Rascio, F., additional, Gigante, M., additional, Castellano, G., additional, Schena, A., additional, Fiorentino, M., additional, Zito, A., additional, Zaza, G., additional, Stallone, G., additional, Gesualdo, L., additional, Grandaliano, G., additional, Pattonieri, E. F., additional, Gregorini, M., additional, Corradetti, V., additional, Rocca, C., additional, Milanesi, S., additional, Peloso, A., additional, Ferrario, J., additional, Cannone, M., additional, Bosio, F., additional, Maggi, N., additional, Avanzini, M. A., additional, Minutillo, P., additional, Paulli, M., additional, Maestri, M., additional, Rampino, T., additional, Dal Canton, A., additional, Wu, K. S. T., additional, Coxall, O., additional, Luque, Y., additional, Candon, S., additional, Rabant, M., additional, Noel, L.-H., additional, Thervet, E., additional, Chatenoud, L., additional, Snanoudj, R., additional, Anglicheau, D., additional, Legendre, C., additional, Zuber, J., additional, Hruba, P., additional, Brabcova, I., additional, Krepsova, E., additional, Slatinska, J., additional, Sekerkova, A., additional, Striz, I., additional, Zachoval, R., additional, Viklicky, O., additional, Scholbach, T. M., additional, Wang, H.-K., additional, Loong, C.-C., additional, Yang, A.-H., additional, Wu, T.-H., additional, Guberina, H., additional, Rebmann, V., additional, Dziallas, P., additional, Dolff, S., additional, Wohlschlaeger, J., additional, Heinemann, F. M., additional, Witzke, O., additional, Zoet, Y. M., additional, Claas, F. H. J., additional, Horn, P. A., additional, Kribben, A., additional, Doxiadis, I. I. N., additional, Prasad, N., additional, Yadav, B., additional, Agarwal, V., additional, Jaiswal, A., additional, Rai, M., additional, Hope, C. M., additional, Coates, P. T., additional, Heeger, P. S., additional, Carroll, R., additional, Masola, V., additional, Secchi, M. F., additional, Onisto, M., additional, Gambaro, G., additional, Lupo, A., additional, Matsuyama, M., additional, Kobayashi, T., additional, Yoneda, Y., additional, Chargui, J., additional, Touraine, J. L., additional, Yoshimura, R., additional, Vizza, D., additional, Perri, A., additional, Lupinacci, S., additional, Toteda, G., additional, Lofaro, D., additional, Leone, F., additional, Gigliotti, P., additional, La Russa, A., additional, Papalia, T., additional, Bonofilgio, R., additional, Sentis Fuster, A., additional, Kers, J., additional, Yapici, U., additional, Claessen, N., additional, Bemelman, F. J., additional, Ten Berge, I. J. M., additional, Florquin, S., additional, Glotz, D., additional, Rostaing, L., additional, Squifflet, J.-P., additional, Merville, P., additional, Belmokhtar, C., additional, Le Ny, G., additional, Lebranchu, Y., additional, Papazova, D. A., additional, Friederich-Persson, M., additional, Koeners, M. P., additional, Joles, J. A., additional, Verhaar, M. C., additional, Trivedi, H. L., additional, Vanikar, A. V., additional, Dave, S. D., additional, Suarez Alvarez, B., additional, Garcia Melendreras, S., additional, Carvajal Palao, R., additional, Diaz Corte, C., additional, Ruiz Ortega, M., additional, Lopez-Larrea, C., additional, Yadav, A. K., additional, Bansal, D., additional, Kumar, V., additional, Minz, M., additional, Jha, V., additional, Kaminska, D., additional, Koscielska-Kasprzak, K., additional, Chudoba, P., additional, Mazanowska, O., additional, Banasik, M., additional, Zabinska, M., additional, Boratynska, M., additional, Lepiesza, A., additional, Korta, K., additional, Klinger, M., additional, Csohany, R., additional, Prokai, A., additional, Pap, D., additional, Balicza-Himer, N., additional, Vannay, A., additional, Fekete, A., additional, Kis-Petik, K., additional, Peti-Peterdi, J., additional, Szabo, A., additional, Masajtis-Zagajewska, A., additional, Muras, K., additional, Niewodniczy, M., additional, Nowicki, M., additional, Pascual, J., additional, Srinivas, T. R., additional, Chadban, S., additional, Citterio, F., additional, Henry, M., additional, Oppenheimer, F., additional, Lee, P.-C., additional, Tedesco-Silva, H., additional, Zeier, M., additional, Watarai, Y., additional, Dong, G., additional, Hexham, M., additional, Bernhardt, P., additional, Vincenti, F., additional, Rocchetti, M. T., additional, Su owicz, J., additional, Wojas-Pelc, A., additional, Ignacak, E., additional, Janda, K., additional, Krzanowski, M., additional, Su owicz, W., additional, Mitsuhashi, M., additional, Murakami, T., additional, Benso, A., additional, Leuning, D., additional, Reinders, M., additional, Lievers, E., additional, Duijs, J., additional, Van Zonneveld, A. J., additional, Van Kooten, C., additional, Engelse, M., additional, Rabelink, T., additional, Assounga, A., additional, Omarjee, S., additional, Ngema, Z., additional, Ersoy, A., additional, Gultepe, A., additional, Isiktas Sayilar, E., additional, Akalin, H., additional, Coskun, F., additional, Oner Torlak, M., additional, Ayar, Y., additional, Riegersperger, M., additional, Plischke, M., additional, Steinhauser, C., additional, Jallitsch-Halper, A., additional, Sengoelge, G., additional, Winkelmayer, W. C., additional, Sunder-Plassmann, G., additional, Foedinger, M., additional, Kaziuk, M., additional, Kuz'Niewski, M., additional, B Tkowska- Prokop, A., additional, Pa Ka, K., additional, Dumnicka, P., additional, Kolber, W., additional, and Su Owicz, W., additional

Published
2014
Full Text
View/download PDF

45. Multiple intracranial abscesses due to Cryptococcus neoformans: an unusual clinical feature in an immunocompetent patient and a short review of reported cases

Author

Tore, O., Akcaglar, S., Kazak, E., Heper, Y., Akalin, H., Hakyemez, B., Ener, B., Boekhout, T., Hagen, F., Tore, O., Akcaglar, S., Kazak, E., Heper, Y., Akalin, H., Hakyemez, B., Ener, B., Boekhout, T., and Hagen, F.

Abstract

We present a case of multiple intracranial abscesses caused by Cryptococcus neoformans in a patient who presented with no symptoms of immunodeficiency., We present a case of multiple intracranial abscesses caused by Cryptococcus neoformans in a patient who presented with no symptoms of immunodeficiency.

Published
2010

46. Transplantation - clinical studies II

Author

Marques, I. B., primary, Silva, R. d. M., additional, Moraes, C. E., additional, Azevedo, L. S., additional, Nahas, W. C., additional, David-Neto, E., additional, Furmanczyk-Zawiska, A., additional, Baczkowska, T., additional, Chmura, A., additional, Szmidt, J., additional, Durlik, M., additional, Joslin, J., additional, Blaker, P., additional, White, B., additional, Marinaki, A., additional, Sanderson, J., additional, Goldsmith, D. J., additional, Medani, S., additional, Traynor, C., additional, Mohan, P., additional, Little, D., additional, Conlon, P., additional, Molina, M., additional, Gonzalez, E., additional, Gutierrez, E., additional, Sevillano, A., additional, Polanco, N., additional, Morales, E., additional, Hernandez, A., additional, Praga, M., additional, Morales, J. M., additional, Andres, A., additional, Park, S. J., additional, Kim, T. H., additional, Kim, Y. W., additional, Kim, Y. H., additional, Kang, S. W., additional, Kujawa-Szewieczek, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Kolonko, A., additional, Mahrova, A., additional, Svagrova, K., additional, Bunc, V., additional, Stollova, M., additional, Teplan, V., additional, Hundt, F., additional, van Heteren, P., additional, Woitas, R., additional, Cavallo, M. C., additional, Sepe, V., additional, Conte, F., additional, Albrizio, P., additional, Bottazzi, A., additional, Geraci, P. M., additional, Alpay, N., additional, Gumber, M. R., additional, Kute, V. B., additional, Vanikar, A. V., additional, Patel, H. V., additional, Shah, P. R., additional, Engineer, D. P., additional, Trivedi, H. L., additional, Golebiewska, J. E., additional, Debska-Slizien, A., additional, Rutkowski, B., additional, Matias, P., additional, Martins, A. R., additional, Raposo, L., additional, Jorge, C., additional, Weigert, A., additional, Birne, R., additional, Bruges, M., additional, Adragao, T., additional, Almeida, M., additional, Mendes, M., additional, Machado, D., additional, Masin-Spasovska, J., additional, Dohcev, S., additional, Stankov, O., additional, Stavridis, S., additional, Saidi, S., additional, Dejanova, B., additional, Rambabova-Busletic, I., additional, Dejanov, P., additional, Spasovski, G., additional, Nho, K. W., additional, Han, D. J., additional, Park, S.-K., additional, Kim, S. B., additional, Fenoglio, R., additional, Lazzarich, E. E., additional, Cagna, D., additional, Cena, T., additional, Conti, N., additional, Quaglia, M., additional, Radin, E., additional, Izzo, C., additional, Stratta, P., additional, Oh, I. H., additional, Park, J.-S., additional, Lee, C. H., additional, Kang, C. M., additional, Kim, G.-H., additional, Leone, F., additional, Lofaro, D., additional, Gigliotti, P., additional, Lupinacci, S., additional, Toteda, P., additional, Vizza, D., additional, Perri, A., additional, Papalia, T., additional, Bonofiglio, R., additional, di Loreto, P., additional, de Silvestro, L., additional, Montanaro, D., additional, Martino, F., additional, Sandrini, S., additional, Minetti, E., additional, Cabiddu, G., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Abudalal, A., additional, Altindal, M., additional, Ertoy-Baydar, D., additional, Erdem, Y., additional, Panuccio, V., additional, Tripepi, R., additional, Parlongo, G., additional, Versace, M. C., additional, Politi, R., additional, Zoccali, C., additional, Mallamaci, F., additional, Porrini, E., additional, Silva, I., additional, Diaz, J., additional, Ibernon, M., additional, Moreso, F., additional, Benitez, R., additional, Delgado Mallen, P., additional, Osorio, J., additional, Lauzurica, R., additional, Torres, A., additional, Ersoy, A., additional, Koca, N., additional, Gullu Koca, T., additional, Kirhan, E., additional, Sarandol, E., additional, Ersoy, C., additional, Dirican, M., additional, Milne, J., additional, Suter, V., additional, Mikhail, A., additional, Akalin, H., additional, Dizdar, O., additional, Pascual, J., additional, Torio, A., additional, Garcia, C., additional, Hernandez, J., additional, Perez-Saez, M. J., additional, Mir, M., additional, Anna, F., additional, Crespo, M., additional, Carta, P., additional, Zanazzi, M., additional, Antognoli, G., additional, Di Maria, L., additional, Caroti, L., additional, Ray, D. S., additional, Mukherjee, K., additional, Bohidar, N. P., additional, Pattanaik, A., additional, Das, P., additional, Thukral, S., additional, Kimura, T., additional, Yagisawa, T., additional, Ishikawa, N., additional, Sakuma, Y., additional, Fujiwara, T., additional, Nukui, A., additional, Gavela, E. E., additional, Sancho, A. A., additional, Kanter, J. J., additional, Avila, A. A., additional, Beltran, S. S., additional, Pallardo, L. L., additional, Dawoud, F. G., additional, Aithal, V., additional, Majernikova, M., additional, Rosenberger, J., additional, Prihodova, L., additional, Nagyova, I., additional, Jarcuskova, M., additional, Roland, R., additional, Groothoff, J. W., additional, van Dijk, J. P., additional, van Agteren, M., additional, de Weerd, A., additional, van de Wetering, J., additional, IJzermans, J., additional, Betjes, M., additional, Weimar, W., additional, Popoola, J., additional, Reed, A., additional, Tavarro, R., additional, Chryssanthopoulou, C., additional, MacPhee, I., additional, Mayor, M., additional, Franco, S., additional, Jara, P., additional, Ayala, R., additional, Orue, M. G., additional, Martinez, A., additional, Martinez, M., additional, Wasmouth, N., additional, Arik, G., additional, Yasar, A., additional, Yilmaz, S., additional, Arici, M., additional, Bihari Bansal, S., additional, Pokhariyal, S., additional, Jain, S., additional, Sethi, S., additional, Ahlawat, R., additional, Kher, V., additional, Martins, L. S., additional, Aguiar, P., additional, Dias, L., additional, Fonseca, I., additional, Henriques, A. C., additional, Cabrita, A., additional, Davide, J., additional, Sparkes, T. M., additional, Trofe-Clark, J., additional, Reese, P. P., additional, Jakobowski, D., additional, Goral, S., additional, Doll, S. L., additional, Abt, P. L., additional, Sawinski, D., additional, MBloom, R. D., additional, Knap, B., additional, Lukac, J., additional, Lukin, M., additional, Majcen, I., additional, Pavlovec, F., additional, Kandus, A., additional, Bren, A. F., additional, Kong, J. M., additional, Jeong, J. H., additional, Ahn, J., additional, Lee, D. R., additional, Son, S. H., additional, Kim, B. C., additional, Choi, W. Y., additional, Whang, E. J., additional, Czajka, B., additional, Malgorzewicz, S., additional, Panizo, N., additional, Rengel, M. A., additional, Vega, A., additional, Abad, S., additional, Tana, L., additional, Arroyo, D., additional, Rodriguez-Ferrero, M., additional, Perez de Jose, A., additional, Lopez-Gomez, J. M., additional, Koutroutsos, K., additional, Sackey, J., additional, Paolini, L., additional, Ramkhelawon, R., additional, Chowrimootoo, M., additional, Whelan, D., additional, Slatinska, J., additional, Honsova, E., additional, Wohlfahrtova, M., additional, Slimackova, E., additional, Rajnochova, S. B., additional, Viklicky, O., additional, Yankovoy, A., additional, Smith, I. S. J., additional, Wylie, E., additional, Ruiz-Esteban, P., additional, Lopez, V., additional, Garcia-Frias, P., additional, Cabello, M., additional, Gonzalez-Molina, M., additional, Vozmediano, C., additional, Hernandez, D., additional, Pavlovic, J., additional, Radivojevic, D., additional, Lezaic, V., additional, Simic-Ogrizovic, S., additional, Lausevic, M., additional, Naumovic, R., additional, Sakhuja, V., additional, Gundlapalli, S., additional, Rathi, M., additional, Jha, V., additional, Kohli, H. S., additional, Sharma, A., additional, Minz, M., additional, Nimgirova, A., additional, Esayan, A., additional, Kayukov, I., additional, Zuyeva, E., additional, Bilen, Y., additional, Cankaya, E., additional, Keles, M., additional, Gulcan, E., additional, Turkeli, M., additional, Albayrak, B., additional, Uyanik, A., additional, Yildirim, R., additional, Molitor, N., additional, Praktiknjo, M., additional, Abeygunaratne, T. N., additional, Balasubramanian, S., additional, Baker, R., additional, Nicholson, T., additional, Toprak, O., additional, Sari, Y., additional, Keceli, S., additional, Kurt, H., additional, Rocha, A., additional, Malheiro, J., additional, Pedroso, S., additional, Henriques, A., additional, Nihei, C., additional, Bacelar Marques, I., additional, Seguro, C. A., additional, Mate, G., additional, Martin, N., additional, Colon, L., additional, Casellas, L., additional, Garangou, D., additional, de la Torre, M., additional, Torguet, P., additional, Garcia, I., additional, Calabia, J., additional, Valles, M., additional, Pruthi, R., additional, Calestani, M., additional, Leydon, G., additional, Ravanan, R., additional, Roderick, P., additional, Korkmaz, S., additional, and Gulten, S., additional

Published
2013
Full Text
View/download PDF

47. Expression of Glutamate Transporters in Alcohol Withdrawal.

Author

Ozsoy, S., Asdemir, A., Karaaslan, O., Akalin, H., Ozkul, Y., and Esel, E.

Subjects
GLUTAMATE transporters, ALCOHOL withdrawal syndrome, AMINO acids, POLYMERASE chain reaction, PEOPLE with alcoholism, CARRIER proteins, MEMBRANE proteins
Abstract

Introduction: The study aimed to investigate the expression of glutamate transporters during withdrawal in the alcohol-dependent patients. Method: The study consisted of 20 male inpatient alcoholics during the withdrawal period and 20 healthy controls. Expressions of glutamate transporters, namely the excitatory amino acid transporter 2 (EAAT2) and EAAT3, in white blood cells were measured with the real-time polymerase chain reaction (RT-PCR) method in early (first day) and late (28th day) withdrawal in alcoholic patients and once in the controls. Results: EAAT2 and EAAT3 expressions in the patients during both early and late withdrawal were higher than those of the controls. There was no difference in the EAAT2 and EAAT3 levels of the patients between early and late abstinence. Discussion: The study revealed an upregulation of glutamate transporters EAAT2 and EAAT3 during early and late withdrawal in patients with alcohol withdrawal. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results